Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III Study of Evobrutinib vs Interferon beta-1a (Avonex) in Relapsing Multiple Sclerosis
2018-004701-11Phase 3Terminated
- Sponsor
- Merck KGaA
- Start
- Jan 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of evobrutinib in multiple sclerosis (MS) (2 arms), sponsored by Merck KGaA. Primary endpoint: Annualized Relapse Rate at Week 96. Started Jan 2020; status: terminated.
02
Drugs
evobrutinib
03
Conditions
multiple sclerosis (MS)
Beyond the preview
Go deeper on 2018-004701-11.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-004701-11.